Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro

Basic and Clinical Pharmacology and Toxicology

Volumn 98, Issue 1, 2006, Pages 79-85

  Granfors, Marika T ^a   Wang, Jun Sheng ^a,b   Kajosaari, Lauri I ^a   Laitila, Jouko ^a   Neuvonen, Pertti J ^a   Backman, Janne T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RECOMBINANT ENZYME; RITONAVIR; SAQUINAVIR;

ARTICLE; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FETUS DEVELOPMENT; HUMAN IMMUNODEFICIENCY VIRUS; HYDROXYLATION; IN VITRO STUDY; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CARBAMATES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYLATION; INDINAVIR; ISOENZYMES; KINETICS; NELFINAVIR; RECOMBINANT PROTEINS; RITONAVIR; SAQUINAVIR; SULFONAMIDES; TESTOSTERONE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33645098680     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_249.x     Document Type: Article

References (52)

1. Anglicheau D. D. Le Corre S. Lechaton P. Laurent-Puig H. Kreis P. Beaune C. Legendre E. Thervet Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy Amer. J. Transplant. 2005 5 595 603
2. Chen H. A. G. Fantel M. R. Juchau Catalysis of the 4-hydroxylation of retinoic acids by CYP3A7 in human fetal hepatic tissues Drug Metab. Dispos. 2000 28 1051 1057
3. Cheng C. H. C. Miller C. Lowe, V. E. Pearson Rhabdomyolysis due to probable interaction between simvastatin and ritonavir Amer. J. Health. Syst. Pharm. 2002 59 728 730
4. Chiba M. M. Hensleigh J. A. Nishime S. K. Balani J. H. Lin Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor Drug Metab. Dispos. 1996 24 307 314
5. Chou F.-C. S.-J. Tzeng J.-D. Huang Genetic polymorphism of cytochrome P450 3A5 in Chinese Drug Metab. Dispos. 2001 29 1205 1209
6. Decker C. J. L. M. Laitinen G. W. Bridson S. A. Raybuck R. D. Tung P. R. Chaturvedi Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions J. Pharm. Sci. 1998 87 803 807
7. de Wildt S. N. G. L. Kearns J. S. Leeder J. N. van den Anker Cytochrome P450 3A: ontogeny and drug disposition Clin. Pharmacokinet. 1999 37 485 505
8. Domanski T. L. C. Finta J. R. Halpert P. G. Zaphiropoulos cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450 Mol. Pharmacol. 2001 59 386 392
9. Eagling V. A. D. J. Back M. G. Barry Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir Brit. J. Clin. Pharmacol. 1997 44 190 194
10. Ernest C. S. 2nd. S. D. Hall D. R. Jones Mechanism-based inactivation of CYP3A by HIV protease inhibitors J. Pharmacol. Exp. Therap. 2005 312 583 591
11. Fichtenbaum C. J. J. G. Gerber Interactions between antoretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection Clin. Pharmacokinet. 2002 41 1195 1211
12. Fitzsimmons M. E. J. M. Collins Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism Drug Metab. Dispos. 1997 25 256 266
13. Fröhlich M. M. M. Hoffmann J. Burhenne G. Mikus J. Weiss W. E. Haefeli Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics Brit. J. Clin. Pharmacol. 2004 58 443 444
14. Gellner K. R. Eiselt E. Hustert H. Arnold I. Koch M. Haberl C. J. Deglmann O. Burk D. Buntefuss S. Escher C. Bishop H. G. Koebe U. Brinkmann H. P. Klenk K. Kleine U. A. Meyer L. Wojnowski Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene Pharmacogenetics 2001 11 111 121
15. Gibbs M. A. K. E. Thummel D. D. Shen K. L. Kunze Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression Drug Metab. Dispos. 1999 27 180 187
16. Haufroid V. M. Mourad V. Van Kerckhove J. Wawrzyniak M. De Meyer D. C. Eddour J. Malaise D. Lison J. P. Squifflet P. Wallemacq The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 2004 14 147 154
17. Hesselink D. A. R. H. van Schaik I. P. van der Heiden M. van der Werf P. J. Gregoor J. Lindemans W. Weimar T. van Gelder Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin. Pharmacol. Therap. 2003 74 245 254
18. Hustert E. M. Haberl O. Burk R. Wolbold, Y.-Q. He K. Klein A. C. Nuessler P. Neuhaus J. Klattig R. Eiselt I. Koch A. Zibat J. Brockmöller J. R. Halpert U. M. Zanger L. Wojnowski The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 2001 11 773 779
19. Inaba T. N. E. Fischer D. S. Riddick D. J. Stewart T. Hidaka HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes Toxicol. Lett. 1997 93 215 219
20. Kato Y. T. Fujii N. Mizoguchi N. Takata K. Ueda M. D. Feldman S. R. Kayser Potential interaction between ritonavir and carbamazepine Pharmacotherapy 2000 20 851 854
21. Katz D. A. D. R. Grimm S. C. Cassar M. C. Gentile X. Ye M. J. Rieser E. F. Gordon J. E. Polzin L. E. Gustavson R. M. Driscoll R. F. O'dea L. A. Williams S. Bukofzer CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels Clin. Pharmacol. Therap. 2004 75 516 528
22. Kelly D. V. L. C. Beique M. I. Bowmer Extrapyramidal symptoms with ritonavir/indinavir plus risperidone Ann. Pharmacother. 2002 36 827 830
23. Kitada M. T. Kamataki K. Itahashi T. Rikihisa Y. Kanakubo P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16α-hydroxylase of dehydroepiandrosterone 3-sulfate J. Biol. Chem. 1987 262 13534 13537
24. Kivistö K. T. M. Niemi E. Schaeffeler K. Pitkälä R. Tilvis M. F. Fromm M. Schwab M. Eichelbaum T. Strandberg Lipid-lowering response to statins is affected by CYP3A5 polymorphism Pharmacogenetics 2004 14 523 525
25. Klees T. M. P. Sheffels K. E. Thummel E. D. Kharasch Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5 Anesthesiology 2005 102 550 556
26. Koch I. R. Weil R. Wolbold J. Brockmöller E. Hustert O. Burk A. Nuessler P. Neuhaus M. Eichelbaum U. Zanger L. Wojnowski Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA Drug Metab. Dispos. 2002 30 1108 1114
27. Koudriakova T. E. Iatsimirskaia I. Utkin E. Gangl P. Vouros E. Storozhuk D. Orza J. Marinina N. Gerber Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir Drug Metab. Dispos. 1998 26 552 561
28. Krusekopf S. I. Roots U. Kleeberg Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43 Eur. J. Pharmacol. 2003 466 7 12
29. Kuehl P. J. Zhang Y. Lin J. Lamba M. Assem J. Schuetz P. B. Watkins A. Daly S. A. Wrighton S. D. Hall P. Maurel M. Relling C. Brimer K. Yasuda R. Venkataramanan S. Strom K. Thummel M. S. Boguski E. Schuetz Sequence diversity in CYP3A promoters and chacterization of the genetic basis of polymorphic CYP3A5 expression Nat. Genet. 2001 27 383 391
30. Kumar G. N. A. D. Rodrigues A. M. Buko J. F. Denissen Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitir ritonavir (ABT-538) in human liver microsomes J. Pharmacol. Exp. Therap. 1996 277 423 431
31. Lamba J. K. Y. S. Lin E. G. Schuetz K. E. Thummel Genetic contribution to variable human CYP3A-mediated metabolism Adv. Drug. Deliv. Rev. 2002 54 1271 1294
32. Lillibridge J. H. B. H. Liang B. M. Kerr S. Webber B. Quart B. V. Shetty C. A. Lee Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human human immunodeficiency virus-protease inhibitor nelfinavir mesylate Drug Metab. Dispos. 1998 26 609 616
33. Lin Y. S. A. L. S. Dowling S. D. Quigley F. M. Farin J. Zhang J. Lamba E. G. Schuetz K. E. Thummel Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism Mol. Pharmacol. 2002 62 162 172
34. MacPhee I. A. S. Fredericks T. Tai P. Syrris N. D. Carter A. Johnston L. Goldberg D. W. Holt Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement Transplantation 2002 74 1486 1489
35. McConn D. J. 2nd. Y. S. Lin K. Allen K. L. Kunze T. E. Thummel Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs Drug Metab. Dispos. 2004 32 1083 1091
36. Marzolini C. C. Rudin L. A. Decosterd A. Telenti A. Schreyer J. Biollaz T. Buclin the Swiss Mother + Child HIV Cohort Study Transplacental passage of protease inhibitors at delivery AIDS 2002 16 889 893
37. Nelson D. R. L. Koymans T. Kamataki J. J. Stegemann R. Feyereisen D. J. Waxman M. R. Waterman O. Gotoh M. J. Coon R. W. Estabrook I. C. Gunsalus D. W. Nebert P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature Pharmacogenetics 1996 6 1 42
38. Olkkola K. T. V. J. Palkama P. J. Neuvonen Ritonavir's role in reducing fentanyl clearance and prolonging its half-life Anesthesiology 1999 91 681 685
39. Palkama V. J. J. Ahonen P. J. Neuvonen K. T. Olkkola Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam Clin. Pharmacol. Therap. 1999 66 33 39
40. Schuetz J. D. D. L. Beach P. S. Guzelian Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver Pharmacogenetics 1994 4 11 20
41. Tateishi T. M. Watanabe H. Moriya S. Yamaguchi T. Sato S. Kobayashi No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins Biochem. Pharmacol. 1999 57 935 939
42. Thorne C. D. Patel M. L. Newell Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe AIDS 2004 18 2337 2339
43. Tuomala R. E. D. E. Shapiro L. M. Mofenson Y. Bryson M. Culnane M. D. Hughes M. J. O'Sullivan G. Scott A. M. Stek D. Wara M. Bulterys Antiretroviral therapy during pregnancy and the risk of an adverse outcome New Engl. J. Med. 2002 346 1863 1870
44. Unadkat J. D. Y. Wang Antivirals In Metabolic drug interactions Eds. Levy R. H. Thummel K. E. Trager W. F. Hansten P. D. Eichelbaum M. Lippincott Williams & Wilkins Philadelphia, USA 2000 pp. 421 433
45. von Moltke L. L. A. L. B. Durol S. X. Duan D. J. Greenblatt Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole Eur. J. Clin. Pharmacol. 2000 56 259 261
46. von Richter O. O. Burk M. F. Fromm K. P. Thon M. Eichelbaum K. T. Kivistö Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens Clin. Pharmacol. Therap. 2004 75 172 183
47. Wang R. W. D. J. Newton N. Liu W. M. Atkins A. Y. H. Lu Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent Drug Metab. Dispos. 2000 28 360 366
48. Watts D. H. Management of human immunodeficiency virus infection in pregnancy New Engl. J. Med. 2002 346 1879 1891
49. Williams J. A. B. J. Ring V. E. Cantrell D. R. Jones J. Eckstein K. Ruterbories M. A. Hamman S. D. Hall S. A. Wrighton Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7 Drug Metab. Dispos. 2002 30 883 891
50. Wrighton S. A. W. R. Brian, M.-A. Sari M. Iwasaki F. P. Guengerich J. L. Raucy D. T. Molowa M. VandenBranden Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3) Mol. Pharmacol. 1990 38 207 213
51. Wrighton S. A. D. T. Molowa P. S. Guzelian Identification of a cytochrome P-450 in human fetal liver related to glucocorticoid-inducible cytochrome P-450HLp in the adult Biochem. Pharmacol. 1988 37 3053 3055
52. Yeni P. G. S. M. Hammer C. C. J. Carpenter D. A. Cooper M. A. Fischl J. M. Gatell B. G. Gazzard M. S. Hirsch D. M. Jacobsen D. A. Katzenstein J. S. G. Montaner D. D. Richman M. S. Saag M. Schechter R. T. Schooley M. A. Thompson S. Vella P. A. Volberding Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA panel J. Amer. Med. Ass. 2002 288 222 235